Cellectis S.A. (CLLS)
The price, the headline numbers and the latest news, in one place.
Cellectis S.A. (CLLS) Stock Price, Analysis & Data
| Bid | 2.8 |
| Market Cap | 321.24M |
| Revenue (ttm) | 63.82M |
| Net Income (ttm) | -65.31M |
| 2.75 | |
| -0.69 | |
| n/a | |
| -5.15 | |
| P/B (ttm) | 5.65 |
| P/S (ttm) | 5.03 |
| Earnings Date | Nov 13, 2026 |
| Ask | 2.99 |
| Volume | 17,199 |
| Avg. Volume (20D) | 30,198 |
| Open | 3.23 |
| Previous Close | 3.40 |
| Day's Range | 3.13 - 3.28 |
| 52-Week Range | 2.35 - 5.48 |
| Analyst | Buy |
| Price Target | 8 (150.78%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, design...
Financial Performance
In 2025, Cellectis S.A.'s revenue was 72.95M, an increase of 75.76% compared to the previous year's 41.51M. Earnings were -67.59M, an increase of 83.87%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for CLLS stock is "Buy". The 12-month stock price forecast is 8, which is upside of 150.78% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $5.23M misses estimates by $0, with -68.74% YoY decline.
- EPS of -0.22 exceeds estimates by 0.03, with 0.00% YoY growth.
Analysts project revenue of ... Upgrade